Since we had demonstrated uptake of IV administered PNPs into the liver—with good distribution through the key cells in the liver—and, since HCC is one of the worst responding cancers to the immune checkpoint inhibitors, we decided to examine the effect of siRNA administration ± an anti-PDL1 mAb to treat liver cancer. The gene discussed is CD274; the disease is cancer.